Iris D Nagtegaal
Overview
Explore the profile of Iris D Nagtegaal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
316
Citations
13166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katsara M, van den Berg D, Spaander M, van Vuuren A, Dekker E, van Kemenade F, et al.
Int J Cancer
. 2025 Mar;
PMID: 40079681
This study investigates the impact of extended invitation intervals on the stage distribution of screen-detected and interval colorectal cancers (CRCs) in the Netherlands' fecal immunochemical test (FIT)-based screening program during...
2.
Te Groen M, Derks M, Nagtegaal I, Peters C, de Vries A, Dijkstra G, et al.
Eur J Gastroenterol Hepatol
. 2025 Feb;
37(3):287-294.
PMID: 39919003
Objective: The diagnosis of inflammatory bowel disease (IBD) associated with high-grade dysplasia (HGD) has a significant impact on clinical management, including colectomy. However, the prognosis of HGD remains unclear due...
3.
Gonzalez R, Horton R, Zhang X, Graham R, Longacre T, Mehrotra A, et al.
Histopathology
. 2025 Jan;
PMID: 39887413
Aims: We compiled two cohorts of colorectal adenosquamous carcinoma (ASC) to describe its histologic and molecular aspects using modern parameters to compare them with literature reports using meta-analysis of cohorts...
4.
Kryklyva V, Pfluger M, Ouchene H, Volleberg-Gorissen H, Mensenkamp A, Jonker M, et al.
Mod Pathol
. 2025 Jan;
38(5):100709.
PMID: 39793706
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. Approximately 10% of affected individuals have an inherited component. Deleterious germline variants increase the lifetime risk for PDAC and are often associated...
5.
van Stigt B, Lansdorp-Vogelaar I, Spaander M, van Vuuren A, Dekker E, van Kemenade F, et al.
Int J Cancer
. 2024 Dec;
156(9):1783-1790.
PMID: 39697047
Upper age limits are currently fixed for all fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. A risk-stratified upper age limit may be beneficial. Therefore, we assessed differences in...
6.
Hugen N, Loughrey M, Nagtegaal I
Eur J Surg Oncol
. 2024 Dec;
:109457.
PMID: 39638651
No abstract available.
7.
Miyoshi J, Mannucci A, Scarpa M, Gao F, Toden S, Whitsett T, et al.
Gut
. 2024 Nov;
74(2):169-181.
PMID: 39562048
Background: There is no clinically relevant serological marker for the early detection of oesophageal adenocarcinoma (EAC) and its precursor lesion, Barrett's oesophagus (BE). Objective: To develop and test a blood-based...
8.
Kus Ozturk S, Bokhorst J, Baumann E, Sheahan K, van de Velde C, Marijnen C, et al.
Mod Pathol
. 2024 Nov;
38(2):100655.
PMID: 39522647
Owing to insufficient evidence, tumor budding (TB) is not currently evaluated in colorectal cancer (CRC) biopsies. This study investigates TB in CRC by establishing the value of intratumoral budding (ITB)...
9.
Iyer K, Poel D, Miggelenbrink A, Kerkhof W, Janssen J, Bakkerus L, et al.
BJC Rep
. 2024 Nov;
2(1):29.
PMID: 39516561
Background: Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs have, high-dose regimens that trigger...
10.
Jacobs F, Groenhuis V, de Jong I, Nagtegaal I, Rovers M, Bulte G, et al.
Surg Endosc
. 2024 Nov;
38(12):7677-7686.
PMID: 39496951
Background: As a result of recent advances in the development of small microelectromechanical system mirrors, a novel forward-looking optical coherence tomography (OCT) probe with a uniquely large field of view...